SYBX on OTC

SYNLOGIC, INC.

American pharmaceutical preparations company, incorporated in Delaware.

$1.08 up 0.06 (5.88%)Price as of Oct 15, 2026 at 17:33 UTC

Last updated Oct 18, 2026.

Overview

Compare with GENELUX Corp, Azitra, Inc. or Aspire-Lakewood Holdings, Inc., or pick any stock.

TickerSYBX on OTC
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE³
Business addressPo Box 30, Winchester, Ma 01890³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 2025⁴

-8.5%Return on equity⁴

-$4.4MFree cash flow⁴

Financial statements

Revenue⁵⁶⁷⁸⁹⁴$0 in 2025

Operating income⁵⁶⁷⁸⁹⁴-$4.0M in 2025−93% since 2019

Net income⁵⁶⁷⁸⁹⁴-$1.0M in 2025−98% since 2019

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Revenue	$0	$8.0K
Research and development	$43.0K	$9.2M
General and administrative	$3.5M	$6.6M
Restructuring and other charges	$476.0K	$25.2M
Total operating expenses	$4.0M	$41.0M
Loss from operations	-$4.0M	-$41.0M
Interest and investment income	$695.0K	$1.4M
Change in fair value of purchase warrant liability	$2.3M	$16.2M
Other expense	$0	-$2.0K
Total other income (expense), net	$3.0M	$17.6M
Loss before income taxes	-$1.0M	-$23.4M
Income tax expense	$0	-$5.0K
Net loss	-$1.0M	-$23.4M
Net loss per share - basic and diluted	-$0.08	-$1.92
Net loss per share - basic and diluted	-$0.08	-$1.92
Weighted-average common stock outstanding - basic and diluted	12.3M shares	12.2M shares
Weighted-average common stock outstanding - basic and diluted	12.3M shares	12.2M shares
Net unrealized (loss) gain on marketable securities	$0	-$6.0K
Comprehensive loss	-$1.0M	-$23.4M

Total assets⁵⁶⁷⁸⁹⁴$15.4M in 2025−92% since 2019

Shareholders’ equity⁶⁷⁸⁹⁴$11.9M in 2025−92% since 2019

Cash⁵⁶⁷⁸⁹⁴$14.7M in 2025−44% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$14.7M	$18.9M
Prepaid expenses and other current assets	$729.0K	$830.0K
Assets held for sale	$0	$86.0K
Total current assets	$15.4M	$19.8M
Restricted cash	$50.0K	$50.0K
Total assets	$15.4M	$19.8M
Accounts payable	$103.0K	$164.0K
Accrued expenses	$915.0K	$2.0M
Purchase warrant laibility	$2.6M	$4.9M
Total current liabilities	$3.6M	$7.1M
Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 11,978,711 shares issued and 11,698,919 shares outstanding as of December 31, 2025 and 11,975,901 shares issued and 11,696,109 shares outstanding as of December 31, 2024	$12.0K	$12.0K
Additional paid-in capital	$457.0M	$456.9M
Accumulated other comprehensive income	$0	$0
Accumulated deficit	-$442.7M	-$441.7M
Treasury stock, at cost (279,792 shares at December 31, 2025 and at December 31, 2024)	-$2.5M	-$2.5M
Total stockholders' equity	$11.9M	$12.8M	$32.8M
Total liabilities and stockholders' equity	$15.4M	$19.8M
Common stock, par value	$0.00	$0.00
Common stock, authorized	250.0M shares	250.0M shares
Common stock, Issued	12.0M shares	12.0M shares
Common stock, outstanding	11.7M shares	11.7M shares
Treasury stock, shares	279.8K shares	279.8K shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$14.7M	$18.9M
Prepaid expenses and other current assets	$729.0K	$830.0K
Assets held for sale	$0	$86.0K
Total current assets	$15.4M	$19.8M
Restricted cash	$50.0K	$50.0K
Total assets	$15.4M	$19.8M
Accounts payable	$103.0K	$164.0K
Accrued expenses	$915.0K	$2.0M
Purchase warrant laibility	$2.6M	$4.9M
Total current liabilities	$3.6M	$7.1M
Common stock, $0.001 par value 250,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 11,978,711 shares issued and 11,698,919 shares outstanding as of December 31, 2025 and 11,975,901 shares issued and 11,696,109 shares outstanding as of December 31, 2024	$12.0K	$12.0K
Additional paid-in capital	$457.0M	$456.9M
Accumulated other comprehensive income	$0	$0
Accumulated deficit	-$442.7M	-$441.7M
Treasury stock, at cost (279,792 shares at December 31, 2025 and at December 31, 2024)	-$2.5M	-$2.5M
Total stockholders' equity	$11.9M	$12.8M	$32.8M
Total liabilities and stockholders' equity	$15.4M	$19.8M
Common stock, par value	$0.00	$0.00
Common stock, authorized	250.0M shares	250.0M shares
Common stock, Issued	12.0M shares	12.0M shares
Common stock, outstanding	11.7M shares	11.7M shares
Treasury stock, shares	279.8K shares	279.8K shares

Cash from operations⁵⁶⁷⁸⁹⁴-$4.4M in 2025−94% since 2019

Capital spending⁵⁶⁷⁸⁹⁴$0 in 2025

Free cash flow⁵⁶⁷⁸⁹⁴-$4.4M in 2025−94% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net loss	-$1.0M	-$23.4M
Depreciation	$0	$347.0K
Gain on disposal of property and equipment	-$81.0K	-$1.2M
Impairment loss on fixed assets	$0	$5.0M
Impairment loss on ROU assets	$0	$9.6M
Gain on lease termination	$0	-$3.3M
Impairment of prepaid research and development	$0	$5.2M
Equity-based compensation expense	$117.0K	$3.2M
Change in fair value warrant liability	-$2.3M	-$16.2M
Accretion/amortization of investment securities	$0	-$242.0K
Reduction in carrying amount of operating lease right of use asset	$0	$948.0K
Prepaid expenses and other current assets	$101.0K	$1.0M
Prepaid research and development, net of current portion	$0	$1.9M
Accounts payable and accrued expenses	-$1.2M	-$2.3M
Operating lease liabilities	$0	-$12.4M
Other assets	$0	$16.0K
Net cash used in operating activities	-$4.4M	-$31.7M
Purchases of marketable securities	$0	-$1.5M
Proceeds from maturity of marketable securities	$0	$25.5M
Purchases of property and equipment	$0	-$14.0K
Proceeds from the sale of property and equipment	$167.0K	$1.3M
Net cash provided by investing activities	$167.0K	$25.3M
Payments on finance lease obligations	$0	-$4.0K
Proceeds from employee stock purchases and exercise of stock options	$0	$152.0K
Net cash provided by financing activities	$0	$172.0K
Net decrease increase in cash, cash equivalents and restricted cash	-$4.2M	-$6.1M
Decrease in right-of-use asset and operating lease liabilities due to lease termination	$0	$1.6M
Property and equipment sales included in other current assets	$0	$2.0K
Cash paid for income taxes	$0	$5.0K

Compare SYNLOGIC, INC. with another company

Leadership

Who has led SYNLOGIC, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

President

Chief financial officer

Chief operating officer

20202025

Chief executive officerAoife Brennan Jun 6, 2018 to Nov 14, 2023¹²
Chief executive officerPaul Lammers Sep 30, 2015 to Mar 14, 2016¹³
PresidentAoife Brennan Jun 6, 2018 to Nov 14, 2023¹²
PresidentPaul Lammers Sep 30, 2015 to Mar 14, 2016¹³
Chief financial officerMichael Vangsted Jensen Mar 3, 2022 to Nov 14, 2023¹⁴
Chief financial officerAlan Fuhrman Sep 30, 2015 to Mar 14, 2016¹⁵
Chief operating officerAntoine Awad Aug 10, 2020 to Apr 4, 2024¹⁶
Chief operating officerAndrew Gengos Mar 15, 2018 to Mar 15, 2018¹⁷

Board members and other officers (34)

Head of FinanceMary Beth Dooley Mar 21, 2024 to now¹⁸
Chief Scientific OfficerScott Eric Plevy May 7, 2019 to Sep 25, 2019¹⁹
Chief Medical OfficerRichard J. Riese Sep 18, 2019 to Mar 12, 2021²⁰
OfficerGregg Beloff Oct 24, 2019 to Feb 1, 2022²¹
Chief Medical OfficerAoife Brennan Aug 30, 2017 to Apr 5, 2023²²
OfficerJose-Carlos Gutierrez-Ramos Aug 30, 2017 to Mar 16, 2018²³
Chief Scientific OfficerPaul Francis Miller Aug 30, 2017 to Feb 14, 2019²⁴
OfficerTodd Shegog Aug 30, 2017 to Mar 6, 2019²⁵
OfficerAndrew Gengos Oct 10, 2017 to Dec 22, 2017²⁶
Chief Medical OfficerVincent O'Neill Apr 26, 2016 to Apr 26, 2016²⁷
Chief Business OfficerCasi Deyoung Sep 30, 2015 to Mar 14, 2016²⁸
Chief Scientific OfficerMiguel Barbosa Sep 30, 2015 to Sep 30, 2015²⁹
Chief Medical OfficerSinil Kim Sep 30, 2015 to Mar 7, 2016³⁰
Board memberAnthony A. Florence Jr. Aug 14, 2026 to now³¹
Board memberMohamad Makhzoumi Aug 14, 2026 to now³¹
Board memberScott Sandell Aug 14, 2026 to now³¹
Board memberLisa Kelly-Croswell Feb 11, 2021 to Jun 26, 2023³²
Board memberMichael Thomas Heffernan Dec 9, 2020 to Jun 26, 2023³³
Board memberPatricia N. Hurter Feb 12, 2019 to Jan 4, 2024³⁴
Board memberAoife Brennan Nov 1, 2018 to Nov 14, 2023³⁵
Board memberChau Quang Khuong Aug 30, 2017 to Apr 22, 2021³⁶
Board memberJose-Carlos Gutierrez-Ramos Aug 30, 2017 to Mar 16, 2018²³
Board memberNick Leschly Aug 30, 2017 to Jun 26, 2023³⁷
Board memberPeter Barrett Aug 30, 2017 to Jan 4, 2024³⁸
Board memberRichard P. Shea Aug 30, 2017 to now³⁹
Board memberSamuel D. Isaly Aug 30, 2017 to Aug 30, 2017⁴⁰
Board memberPeter Greenleaf Mar 2, 2016 to Sep 6, 2016⁴¹
Board memberPerry Nisen Sep 6, 2016 to Sep 6, 2016⁴²
Board memberClay B. Siegall Sep 30, 2015 to Sep 6, 2016⁴³
Board memberEdward T. Mathers Sep 30, 2015 to Jun 26, 2023⁴⁴
Board memberElaine Jones V. Sep 30, 2015 to Sep 30, 2015⁴⁵
Board memberLawrence M. Alleva Sep 30, 2015 to Sep 6, 2016⁴⁶
Board memberMatthew Winkler Sep 30, 2015 to Sep 6, 2016⁴⁷
Board memberPaul Lammers Sep 30, 2015 to Mar 14, 2016¹³

Former names

Mirna Therapeutics, Inc.Aug 23, 2011 to Aug 25, 2017³

Timeline

Jun 6, 2018New chief executive Aoife Brennan becomes CEO¹²
Sep 30, 2015New chief executive Paul Lammers becomes CEO¹³

Filings

182 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 47 major events, 49 insider forms, 22 large holders, 41 other. The latest 20:

Aug 14, 20264 EDGAR
Aug 11, 202610-Q EDGAR
Jul 29, 2026425 EDGAR
Jul 29, 20268-K EDGAR
Jul 29, 2026SCHEDULE 13D/A EDGAR
Jul 29, 2026SCHEDULE 13D/A EDGAR
May 18, 202625-NSE EDGAR
May 14, 202610-Q EDGAR
Apr 30, 202610-K/A EDGAR
Apr 6, 2026SCHEDULE 13D/A EDGAR
Mar 12, 202610-K EDGAR
Jan 29, 20268-K/A EDGAR
Jan 23, 2026SCHEDULE 13G EDGAR
Jan 20, 20268-K EDGAR
Dec 16, 20258-K EDGAR
Nov 26, 20258-K EDGAR
Nov 13, 202510-Q EDGAR
Nov 13, 2025SCHEDULE 13G/A EDGAR
Nov 12, 2025ARS EDGAR
Nov 12, 2025DEF 14A EDGAR

The 182 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 22 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
DRW Securities, LLC	23,763	$16.7K	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARSYNLOGIC, INC. filings on SEC EDGAR
2
Yahoo FinanceSYBX quote
3
SEC EDGARSYNLOGIC, INC. filings on SEC EDGAR
4
SEC EDGARSYNLOGIC, INC. 10-K for fiscal 2025
5
SEC EDGARSYNLOGIC, INC. 10-K for fiscal 2019
6
SEC EDGARSYNLOGIC, INC. 10-K for fiscal 2020
7
SEC EDGARSYNLOGIC, INC. 10-K for fiscal 2021
8
SEC EDGARSYNLOGIC, INC. 10-K for fiscal 2022
9
SEC EDGARSYNLOGIC, INC. 10-K for fiscal 2023
10
SEC EDGARSYNLOGIC, INC. 10-Q for fiscal 2026
11
SEC EDGARSYNLOGIC, INC. 10-Q for fiscal 2026
12
SEC EDGARAoife Brennan, Chief executive officer
13
SEC EDGARPaul Lammers, Chief executive officer
14
SEC EDGARMichael Vangsted Jensen, Chief financial officer
15
SEC EDGARAlan Fuhrman, Chief financial officer
16
SEC EDGARAntoine Awad, Chief operating officer
17
SEC EDGARAndrew Gengos, Chief operating officer
18
SEC EDGARMary Beth Dooley, Head of Finance
19
SEC EDGARScott Eric Plevy, Chief Scientific Officer
20
SEC EDGARRichard J. Riese, Chief Medical Officer
21
SEC EDGARGregg Beloff, Officer
22
SEC EDGARAoife Brennan, Chief Medical Officer
23
SEC EDGARJose-Carlos Gutierrez-Ramos, Officer
24
SEC EDGARPaul Francis Miller, Chief Scientific Officer
25
SEC EDGARTodd Shegog, Officer
26
SEC EDGARAndrew Gengos, Officer
27
SEC EDGARVincent O'Neill, Chief Medical Officer
28
SEC EDGARCasi Deyoung, Chief Business Officer
29
SEC EDGARMiguel Barbosa, Chief Scientific Officer
30
SEC EDGARSinil Kim, Chief Medical Officer
31
SEC EDGARAnthony A. Florence Jr., Board member
32
SEC EDGARLisa Kelly-Croswell, Board member
33
SEC EDGARMichael Thomas Heffernan, Board member
34
SEC EDGARPatricia N. Hurter, Board member
35
SEC EDGARAoife Brennan, Board member
36
SEC EDGARChau Quang Khuong, Board member
37
SEC EDGARNick Leschly, Board member
38
SEC EDGARPeter Barrett, Board member
39
SEC EDGARRichard P. Shea, Board member
40
SEC EDGARSamuel D. Isaly, Board member
41
SEC EDGARPeter Greenleaf, Board member
42
SEC EDGARPerry Nisen, Board member
43
SEC EDGARClay B. Siegall, Board member
44
SEC EDGAREdward T. Mathers, Board member
45
SEC EDGARElaine Jones V., Board member
46
SEC EDGARLawrence M. Alleva, Board member
47
SEC EDGARMatthew Winkler, Board member